[
  {
    "ts": null,
    "headline": "What $6,500 a Month Really Looks Like in Retirement at 67",
    "summary": "Retiring at 67 with $6,500 in monthly income places you solidly in middle-class territory, but the financial reality behind that figure is more nuanced than it appears. With average Social Security benefits at $2,017 per month in 2026, a retiree targeting $6,500 needs to generate roughly $4,483 monthly—or $53,796 annually—from personal savings and investments. The ... What $6,500 a Month Really Looks Like in Retirement at 67",
    "url": "https://finnhub.io/api/news?id=6893e956b6faae41cdb1adaa3ed4f00fff9f2f71cae9fb0f95d173a221eb60ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768240904,
      "headline": "What $6,500 a Month Really Looks Like in Retirement at 67",
      "id": 138078048,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Retiring at 67 with $6,500 in monthly income places you solidly in middle-class territory, but the financial reality behind that figure is more nuanced than it appears. With average Social Security benefits at $2,017 per month in 2026, a retiree targeting $6,500 needs to generate roughly $4,483 monthly—or $53,796 annually—from personal savings and investments. The ... What $6,500 a Month Really Looks Like in Retirement at 67",
      "url": "https://finnhub.io/api/news?id=6893e956b6faae41cdb1adaa3ed4f00fff9f2f71cae9fb0f95d173a221eb60ef"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Find insight on U.S. pharmaceutical companies’ cash positions, the Thai health-care sector and more in the latest Market Talks covering the health care sector.",
    "url": "https://finnhub.io/api/news?id=eda3cf4f73b150dab1efe606ce157882d4fca763716cba74b6697431d4686de4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768238940,
      "headline": "Health Care Roundup: Market Talk",
      "id": 138078034,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Find insight on U.S. pharmaceutical companies’ cash positions, the Thai health-care sector and more in the latest Market Talks covering the health care sector.",
      "url": "https://finnhub.io/api/news?id=eda3cf4f73b150dab1efe606ce157882d4fca763716cba74b6697431d4686de4"
    }
  },
  {
    "ts": null,
    "headline": "JPM26: AbbVie and RemeGen kick off deals with $5.6bn oncology agreement",
    "summary": "AbbVie and RemeGen are the first companies to announce a deal at the J.P Morgan Healthcare Conference 2026, with more deals expected in the coming days.",
    "url": "https://finnhub.io/api/news?id=2666d71eb4ac821fad49b14306d7d3f30e001038b23e3e442277f973faaf74a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768236418,
      "headline": "JPM26: AbbVie and RemeGen kick off deals with $5.6bn oncology agreement",
      "id": 138076447,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie and RemeGen are the first companies to announce a deal at the J.P Morgan Healthcare Conference 2026, with more deals expected in the coming days.",
      "url": "https://finnhub.io/api/news?id=2666d71eb4ac821fad49b14306d7d3f30e001038b23e3e442277f973faaf74a5"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Down 3% in a Month: Why Holding the Stock Still Makes Sense",
    "summary": "ABBV stock falls 3% in a month amid takeover rumor denials, but Skyrizi and Rinvoq momentum and a deep pipeline support staying invested.",
    "url": "https://finnhub.io/api/news?id=58765a627d9be58ce6cb0cd8fcb045fda1cc5bb353794f942837148ac1ed4ae8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768225860,
      "headline": "AbbVie Down 3% in a Month: Why Holding the Stock Still Makes Sense",
      "id": 138075196,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV stock falls 3% in a month amid takeover rumor denials, but Skyrizi and Rinvoq momentum and a deep pipeline support staying invested.",
      "url": "https://finnhub.io/api/news?id=58765a627d9be58ce6cb0cd8fcb045fda1cc5bb353794f942837148ac1ed4ae8"
    }
  },
  {
    "ts": null,
    "headline": "JPM26: Revolution Medicines in spotlight as industry gears up for dealmaking spree",
    "summary": "Multiple big pharma companies are reported to be circling Revolution, a cancer biotech with a market cap of $23bn.",
    "url": "https://finnhub.io/api/news?id=5f6bd37f57ed8d6e8d3e5d332da6a3b5814c6751e9510a1bd927294c52241b7b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768222478,
      "headline": "JPM26: Revolution Medicines in spotlight as industry gears up for dealmaking spree",
      "id": 138071377,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Multiple big pharma companies are reported to be circling Revolution, a cancer biotech with a market cap of $23bn.",
      "url": "https://finnhub.io/api/news?id=5f6bd37f57ed8d6e8d3e5d332da6a3b5814c6751e9510a1bd927294c52241b7b"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors",
    "summary": "AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 (PD-1)/Vascular Endothelial Growth Factor (VEGF)-targeted bispecific antibody. RC148 is currently being developed by RemeGen as a monotherapy and in combination regimens across multiple advanced solid tumors.",
    "url": "https://finnhub.io/api/news?id=28ce3a61ff49f7fccac6a70d57e5d80a6192b11d5a462a9ae71f21549ad3b635",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768221000,
      "headline": "AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors",
      "id": 138071378,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 (PD-1)/Vascular Endothelial Growth Factor (VEGF)-targeted bispecific antibody. RC148 is currently being developed by RemeGen as a monotherapy and in combination regimens across multiple advanced solid tumors.",
      "url": "https://finnhub.io/api/news?id=28ce3a61ff49f7fccac6a70d57e5d80a6192b11d5a462a9ae71f21549ad3b635"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations",
    "summary": "AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings target and the FDA flipped its position on a cell therapy from Atara.",
    "url": "https://finnhub.io/api/news?id=4c5cd43b9789dda93c2e7019c0a76364351620a7132db313a44e9fefec4c074b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768217040,
      "headline": "AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations",
      "id": 138075441,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings target and the FDA flipped its position on a cell therapy from Atara.",
      "url": "https://finnhub.io/api/news?id=4c5cd43b9789dda93c2e7019c0a76364351620a7132db313a44e9fefec4c074b"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States",
    "summary": "AbbVie (NYSE: ABBV) and West Pharmaceutical Services (NYSE: WST) announced today a definitive agreement for AbbVie to acquire a device manufacturing facility in Tempe, Arizona and associated intellectual property from West. The acquisition of the manufacturing site will significantly expand AbbVie's drug delivery device manufacturing capabilities and capacity.",
    "url": "https://finnhub.io/api/news?id=ac8939b079978297f76c5203c80b3d85f43c27989f0f3359a46d90ef9f10ea61",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768215600,
      "headline": "AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States",
      "id": 138071380,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) and West Pharmaceutical Services (NYSE: WST) announced today a definitive agreement for AbbVie to acquire a device manufacturing facility in Tempe, Arizona and associated intellectual property from West. The acquisition of the manufacturing site will significantly expand AbbVie's drug delivery device manufacturing capabilities and capacity.",
      "url": "https://finnhub.io/api/news?id=ac8939b079978297f76c5203c80b3d85f43c27989f0f3359a46d90ef9f10ea61"
    }
  },
  {
    "ts": null,
    "headline": "West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie",
    "summary": "West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that the company has reached a definitive agreement to sell all manufacturing and supply rights for SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie (NYSE: ABBV) for total consideration of $112.5 million at close, subject to working capital and other adjustments. The definitive agreement, which is subject to certain closing condit",
    "url": "https://finnhub.io/api/news?id=eee722e6bd9a5d798dc451e61f082eb755157a413dff8ba85c2570e2848aa6a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768215600,
      "headline": "West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie",
      "id": 138071379,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that the company has reached a definitive agreement to sell all manufacturing and supply rights for SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie (NYSE: ABBV) for total consideration of $112.5 million at close, subject to working capital and other adjustments. The definitive agreement, which is subject to certain closing condit",
      "url": "https://finnhub.io/api/news?id=eee722e6bd9a5d798dc451e61f082eb755157a413dff8ba85c2570e2848aa6a2"
    }
  },
  {
    "ts": null,
    "headline": "3 No-Brainer Dividend Stocks to Buy Right Now",
    "summary": "The decision about buying these dividend stocks is an easy one.",
    "url": "https://finnhub.io/api/news?id=95738e0352cfce812107dfc8704bfdc1eee3b46614382ced69fe15a2baed2adf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768208700,
      "headline": "3 No-Brainer Dividend Stocks to Buy Right Now",
      "id": 138071381,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The decision about buying these dividend stocks is an easy one.",
      "url": "https://finnhub.io/api/news?id=95738e0352cfce812107dfc8704bfdc1eee3b46614382ced69fe15a2baed2adf"
    }
  },
  {
    "ts": null,
    "headline": "Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery",
    "summary": "Taiwan-based Formosa Pharmaceuticals (\"Formosa\", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil Pharmaceuticals, Co., Ltd (\"Samil\", 000520.KS), for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation and pain following ocular surgery in South Korea. Samil, established in 1947, is one of the most prominent Korean manufactu",
    "url": "https://finnhub.io/api/news?id=9b6cc42c0641dbad316c64a7e4916a4faa3c7cb0a762fecad63fec1aae4725fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768204800,
      "headline": "Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery",
      "id": 138071382,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Taiwan-based Formosa Pharmaceuticals (\"Formosa\", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil Pharmaceuticals, Co., Ltd (\"Samil\", 000520.KS), for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation and pain following ocular surgery in South Korea. Samil, established in 1947, is one of the most prominent Korean manufactu",
      "url": "https://finnhub.io/api/news?id=9b6cc42c0641dbad316c64a7e4916a4faa3c7cb0a762fecad63fec1aae4725fe"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Income: Lanny's November 2025 Summary",
    "summary": "In November, we (my wife and I) received a dividend income total of $1,489.90. Another $1,000+.",
    "url": "https://finnhub.io/api/news?id=910f66ee15121fb871783a170f718075f6f0c37d0196ad9808ff9942f4b03396",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768194720,
      "headline": "Dividend Income: Lanny's November 2025 Summary",
      "id": 138070462,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2221411629/image_2221411629.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "In November, we (my wife and I) received a dividend income total of $1,489.90. Another $1,000+.",
      "url": "https://finnhub.io/api/news?id=910f66ee15121fb871783a170f718075f6f0c37d0196ad9808ff9942f4b03396"
    }
  }
]